King, Valerie A.

From: Paul Johnson [Paul.Johnson@mdsps.com]
Sent: Friday, May 16, 2003 4:28 PM
To: Michael Szwanek; Hans-Juergen.Roethig@pmusa.com; martin.unverdorben@pmusa.com; bettie.l.nelson@pmusa.com; valerie.a.king@pmusa.com; jan.oey@pmusa.com; qiwei.liang@pmusa.com; shixia.feng@pmusa.com; mohamadi.sarkar@pmusa.com; robin.d.kinser@pmusa.com
Cc: Kimberly Prchal; michael.szwanek@mdsps.com; Paul Johnson; Megan McCrory; Nancy Wang
Subject: ICF for EHCK3K6/02/03

Sensitivity: Confidential

AA03468_Phillip_Mc rris_Accord_...

All,

Attached is the ICF for the upcoming EHCK3K6 study. Please review and forward any comments by Friday, May 23rd so that they may be implemented by the IRB submission date (May 28th).

Thank you, and best regards,

Paul Johnson
ICF Coordinator
MDS Pharma Services
402-437-4845

PM3006736964

Source: https://www.industrydocuments.ucsf.edu/docs/lkyx0001